chr1-241511968-T-C
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PM1PM2PM5PP3_StrongPP5_Very_Strong
The NM_000143.4(FH):āc.554A>Gā(p.Gln185Arg) variant causes a missense, splice region change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000000684 in 1,461,548 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 2/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Likely pathogenic (ā ā ). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. Q185H) has been classified as Uncertain significance.
Frequency
Consequence
NM_000143.4 missense, splice_region
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
FH | NM_000143.4 | c.554A>G | p.Gln185Arg | missense_variant, splice_region_variant | Exon 4 of 10 | ENST00000366560.4 | NP_000134.2 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome AF: 6.84e-7 AC: 1AN: 1461548Hom.: 0 Cov.: 31 AF XY: 0.00000138 AC XY: 1AN XY: 727066
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 03, 2024 | This sequence change replaces glutamine, which is neutral and polar, with arginine, which is basic and polar, at codon 185 of the FH protein (p.Gln185Arg). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individuals with leiomyomas (PMID: 11865300, 28300276; internal data). This variant is also known as p.Gln142Arg. ClinVar contains an entry for this variant (Variation ID: 214433). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. Experimental studies have shown that this missense change affects FH function (PMID: 11865300, 16237213, 21445611). For these reasons, this variant has been classified as Pathogenic. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Dec 28, 2017 | The Q185R variant in the FH gene has previously been published in association with hereditary leiomyomatosis and renal cell cancer (Tomlinson et al., 2002; Alam et al., 2005; Muller et al., 2017). Alam et al. (2005) reported decreased FH enzyme activity of 46.1% in a heterozygous individual harboring the Q185R variant. This variant is not observed in large population cohorts (Lek et al., 2016). The Q185R variant is a semi-conservative amino acid substitution, which may impact secondary protein structure as these residues differ in some properties. This substitution occurs at a position that is conserved across species, and is located within the enzyme active site (Picaud et al., 2011). In silico analysis predicts this variant is probably damaging to the protein structure/function. Based on currently available evidence, the Q185R variant is a strong candidate for a pathogenic variant. However, the possibility it is a rare benign variant cannot be excluded. - |
Hereditary leiomyomatosis and renal cell cancer Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Genomic Diagnostic Laboratory, Division of Genomic Diagnostics, Children's Hospital of Philadelphia | Jan 17, 2017 | - - |
Hereditary cancer-predisposing syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Nov 27, 2024 | The p.Q185R pathogenic mutation (also known as c.554A>G), located in coding exon 4 of the FH gene, results from an A to G substitution at nucleotide position 554. The glutamine at codon 185 is replaced by arginine, an amino acid with highly similar properties. This alteration been observed in multiple individuals who have a personal and/or family history that is consistent with FH-associated disease (Ambry internal data; Muller M et al. Clin. Genet. 2017 Dec;92:606-615; Tomlinson IP et al. Nat. Genet. 2002 Apr; 30(4):406-10). Based on internal structural assessment, this alteration destabilizes the structure of the N-terminal lobe (Ajalla Aleixo MA et al. FEBS J. 2019 May;286:1925-1940). This variant was not reported in population-based cohorts in the Genome Aggregation Database (gnomAD) (Lek M et al. Nature. 2016 08;536:285-91). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at